A011000 Stock Overview
A biopharmaceutical company, engages in the research, development, and contract manufacturing of nucleic acid-based biopharmaceuticals. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
GeneOne Life Science, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,145.00 |
| 52 Week High | ₩4,735.00 |
| 52 Week Low | ₩1,996.00 |
| Beta | -2.05 |
| 11 Month Change | -5.92% |
| 3 Month Change | -33.07% |
| 1 Year Change | -30.58% |
| 33 Year Change | -88.34% |
| 5 Year Change | 17.43% |
| Change since IPO | 154.95% |
Recent News & Updates
The Market Doesn't Like What It Sees From GeneOne Life Science, Inc.'s (KRX:011000) Revenues Yet As Shares Tumble 39%
Sep 09
Is GeneOne Life Science (KRX:011000) Using Too Much Debt?
Aug 31Recent updates
The Market Doesn't Like What It Sees From GeneOne Life Science, Inc.'s (KRX:011000) Revenues Yet As Shares Tumble 39%
Sep 09Is GeneOne Life Science (KRX:011000) Using Too Much Debt?
Aug 31Why Investors Shouldn't Be Surprised By GeneOne Life Science, Inc.'s (KRX:011000) Low P/S
Jul 26Is GeneOne Life Science (KRX:011000) Using Debt In A Risky Way?
Mar 20GeneOne Life Science (KRX:011000) Has Rewarded Shareholders With An Exceptional 855% Total Return On Their Investment
Jan 10
Shareholder Returns
| A011000 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 0.9% | -8.1% | 2.9% |
| 1Y | -30.6% | 18.1% | -2.8% |
Return vs Industry: A011000 underperformed the KR Biotechs industry which returned 21.1% over the past year.
Return vs Market: A011000 underperformed the KR Market which returned -4% over the past year.
Price Volatility
| A011000 volatility | |
|---|---|
| A011000 Average Weekly Movement | 7.8% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 11.5% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A011000 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A011000's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1976 | 73 | Young-Keun Park | www.genels.com |
GeneOne Life Science, Inc., a biopharmaceutical company, engages in the research, development, and contract manufacturing of nucleic acid-based biopharmaceuticals. Its small molecule pipeline comprises GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, which is Phase II clinical trial for treatment of COVID-19. The company’s nucleic acid vaccines include GLS-3000 mRNA under feasible study and GLS-5310 DNA under phase 2 stage for the treatment of SARS-CoV-2; GLS-5100 under pre-clinical stage for prevention of herpes zoster; and GLS-5140 under pre-clinical stage for the treatment of SFTS prophylaxis.
GeneOne Life Science, Inc. Fundamentals Summary
| A011000 fundamental statistics | |
|---|---|
| Market cap | ₩171.23b |
| Earnings (TTM) | -₩72.69b |
| Revenue (TTM) | ₩37.97b |
4.5x
P/S Ratio-2.4x
P/E RatioIs A011000 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A011000 income statement (TTM) | |
|---|---|
| Revenue | ₩37.97b |
| Cost of Revenue | ₩45.99b |
| Gross Profit | -₩8.02b |
| Other Expenses | ₩64.67b |
| Earnings | -₩72.69b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -910.57 |
| Gross Margin | -21.12% |
| Net Profit Margin | -191.45% |
| Debt/Equity Ratio | 18.4% |
How did A011000 perform over the long term?
See historical performance and comparison